Atara Biotherapeutics, Inc.
http://www.atarabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Atara Biotherapeutics, Inc.
Pierre Fabre Hopes To Enter US Cancer Space With Atara’s Ebvallo
Deal Snapshot: The French company already holds rights to the allogeneic T-cell therapy in much of the world, but will pay Atara $30m up front to obtain rights in the US, Canada and elsewhere.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
A Master Of Firsts: Pascal Touchon On Atara Bio And The Maturing Cell Therapy Ecosystem
Having led the way to regulatory approval for Kymriah and now Ebvallo, Atara CEO Pascal Touchon reflects on the evolution of cell therapy and what his company is doing differently.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Nina Biotherapeutics, Inc.
- Pinta Biotherapeutics, Inc.
- Santa Maria Biotherapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice